Real-life-persistence to Antifibrotic Treatments (REPEAT)

Boehringer Ingelheim

Status: Active, not recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Treatments: Drug: Nintedanib; Drug: Pirfenidone

Study type: Observational

Funder types: Industry

Identifiers

NCT06485635

1199-0568

Details and patient eligibility

About

This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence rate to AF treatment.

Primary objective of the study is to measure the percentage of patients still treated up to 30 months after AF treatment initiation.

Enrollment: 10,646 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

All patients with a reimbursement of AF treatment between 2018 and 2022 will be included for analysis.

Exclusion criteria

No exclusion criteria will be applied.

Trial design

10,646 participants in 1 patient group

Patients with a reimbursement of AF treatment

Treatment:

Drug: Pirfenidone

Drug: Nintedanib